Loxo Oncology (LOXO) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. FIS
6. DUOL
7. ARM
8. SWKS
9. SPY
10. XYZ

Go back to Loxo Oncology (LOXO) Misses Q2 EPS by 4c

Loxo Oncology Announces Second Quarter 2015 Financial Results and Provides Program Updates

August 5, 2015 6:45 AM EDT

STAMFORD, Conn., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, today reported financial results for the second quarter 2015 ended June 30, 2015 and provided an update on its pipeline.

"Over the last several months, Loxo has delivered important advances against our pipeline priorities," said Josh Bilenker, M.D., chief executive officer of Loxo Oncology. "Last week, we achieved an important milestone with the peer-reviewed publication of the first clinical response to LOXO-101, our tropomyosin receptor kinase (TRK) inhibitor. This... More